Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases
AIM: To evaluate the short-term efficacy of the nonselective endothelin receptor antagonist bosentan in the treatment of pulmonary hypertension (PH) associated with diffuse connective tissue diseases (CTD), as well as its effect on survival in both monotherapy and in combination with other PH-specif...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2014-05-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31477 |
| _version_ | 1818314308218519552 |
|---|---|
| author | A V Volkov N N Iudkina E V Nikolaeva I A Kurmukov S I Glukhova E L Nasonov |
| author_facet | A V Volkov N N Iudkina E V Nikolaeva I A Kurmukov S I Glukhova E L Nasonov |
| author_sort | A V Volkov |
| collection | DOAJ |
| description | AIM: To evaluate the short-term efficacy of the nonselective endothelin receptor antagonist bosentan in the treatment of pulmonary hypertension (PH) associated with diffuse connective tissue diseases (CTD), as well as its effect on survival in both monotherapy and in combination with other PH-specific agents/MATERIAL AND METHODS: The study included 20 CDT-associated PH patients who had been hospitalized in 2009-2013. All the patients had valid diagnoses of scleroderma systematica (SDS) (n=18) or systemic lupus erythematosus (SLE) (n=2). Bosentan was given in an initial dose of 62.5 mg/day twice for 4 weeks, then 125 mg/day twice/RESULTS: Eighteen patents completed therapy at 16 weeks. One patient with Functional Class (FC) IV PH associated with SDS died after 10 weeks of treatment because of PH progression; bosentan was discontinued in another patient following 4 weeks because of the enhanced activity of transaminases. The patients who had completed the investigation showed a significant FC decrease (from 2.9±1.0 to 2.4±1.0 following 16 weeks; р=0.03), an increase in 6-minute walking distance (from 298±140 to 375±94 m; р |
| first_indexed | 2024-12-13T08:47:34Z |
| format | Article |
| id | doaj.art-a7b182bd00b044f0aff9c6a5d2c4a27e |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-13T08:47:34Z |
| publishDate | 2014-05-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-a7b182bd00b044f0aff9c6a5d2c4a27e2022-12-21T23:53:26Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422014-05-01865323928493Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseasesA V VolkovN N IudkinaE V NikolaevaI A KurmukovS I GlukhovaE L NasonovAIM: To evaluate the short-term efficacy of the nonselective endothelin receptor antagonist bosentan in the treatment of pulmonary hypertension (PH) associated with diffuse connective tissue diseases (CTD), as well as its effect on survival in both monotherapy and in combination with other PH-specific agents/MATERIAL AND METHODS: The study included 20 CDT-associated PH patients who had been hospitalized in 2009-2013. All the patients had valid diagnoses of scleroderma systematica (SDS) (n=18) or systemic lupus erythematosus (SLE) (n=2). Bosentan was given in an initial dose of 62.5 mg/day twice for 4 weeks, then 125 mg/day twice/RESULTS: Eighteen patents completed therapy at 16 weeks. One patient with Functional Class (FC) IV PH associated with SDS died after 10 weeks of treatment because of PH progression; bosentan was discontinued in another patient following 4 weeks because of the enhanced activity of transaminases. The patients who had completed the investigation showed a significant FC decrease (from 2.9±1.0 to 2.4±1.0 following 16 weeks; р=0.03), an increase in 6-minute walking distance (from 298±140 to 375±94 m; рhttps://ter-arkhiv.ru/0040-3660/article/view/31477scleroderma systematicapulmonary hypertensionbosentansurvivalright heart catheterization |
| spellingShingle | A V Volkov N N Iudkina E V Nikolaeva I A Kurmukov S I Glukhova E L Nasonov Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases Терапевтический архив scleroderma systematica pulmonary hypertension bosentan survival right heart catheterization |
| title | Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases |
| title_full | Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases |
| title_fullStr | Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases |
| title_full_unstemmed | Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases |
| title_short | Bosentan: A considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases |
| title_sort | bosentan a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases |
| topic | scleroderma systematica pulmonary hypertension bosentan survival right heart catheterization |
| url | https://ter-arkhiv.ru/0040-3660/article/view/31477 |
| work_keys_str_mv | AT avvolkov bosentanaconsiderableincreaseinthesurvivalofpatientswithpulmonaryhypertensionassociatedwithsystemicrheumaticdiseases AT nniudkina bosentanaconsiderableincreaseinthesurvivalofpatientswithpulmonaryhypertensionassociatedwithsystemicrheumaticdiseases AT evnikolaeva bosentanaconsiderableincreaseinthesurvivalofpatientswithpulmonaryhypertensionassociatedwithsystemicrheumaticdiseases AT iakurmukov bosentanaconsiderableincreaseinthesurvivalofpatientswithpulmonaryhypertensionassociatedwithsystemicrheumaticdiseases AT siglukhova bosentanaconsiderableincreaseinthesurvivalofpatientswithpulmonaryhypertensionassociatedwithsystemicrheumaticdiseases AT elnasonov bosentanaconsiderableincreaseinthesurvivalofpatientswithpulmonaryhypertensionassociatedwithsystemicrheumaticdiseases |